Ventripoint Issues Shares for Debt Settlement and Awards Option Grants

(TheNewswire)

Toronto, Ontario – TheNewswire - January 28, 2026 –Ventripoint Diagnostics Ltd. ("Ventripoint" orthe "Corporation", TSXV:VPT) is pleased to announce that it received approval from the TSX Venture Exchange(“TSXV”) and has issued 4,276,964 common shares (the “Shares”) of theCorporation to settle an aggregate of$427,696.35 of debt owed to certain arm’s length creditors of theCorporation at a price of $0.10 per share.

The Shares are subject to a hold period of four monthsand one day. The Corporation determined to satisfy the indebtednesswith Shares in order to preserve its cash for development of itsbusiness.

The Company has also issued option grants on January 20, 2026, the Corporation granted an aggregate of2,516,500 options to directors, officers, employees, contractors andconsultants of the Corporation with an exercise price of $0.12 andterms of between 2 (two) to 10 (ten) years, vesting from immediatelyto over a 3 (three) year period. Of these option grants, 200,000 wereawarded to directors and an additional 1,300,000 were awarded toofficers some of which are also directors of the Corporation. 

These annual option grants are an important part ofincentivizing stakeholders to drive value in the Corporation.

Since the last update (see NR June 17, 2025), atotal of 780,000 options were exercised with a weighted average priceof approximately $0.105 per share for gross proceeds to theCorporation of $81,800.00.  There are currently 16,683,500 option grants outstandingwith exercise prices between $0.10 to $0.50 with a weighted averageprice of $0.17, and 14,555,167 of these option grants have vested.

The Corporation has approximately 2.0 million options available for future grants under the Stock OptionPlan as approved by shareholders at the last Special and AnnualGeneral Meeting of the Corporation.

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary knowledge-based reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Corporation. Although the Corporation believes that theexpectations and assumptions on which such forward-looking statementsand information are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCorporation can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in theCorporation's most recent annual management's discussion andanalysis that is available on the Corporation's profile on SEDAR+at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors isnot exhaustive. The forward-looking statements included in this newsrelease are expressly qualified by this cautionary statement. Theforward-looking statements and information contained in this newsrelease are made as of the date hereof and the Corporation undertakesno obligation to update publicly or revise any forward-lookingstatements or information, whether as a result of new information,future events or otherwise, unless so required by applicablesecurities laws.

NOT FOR DISTRIBUTION TOUNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITEDSTATES

Copyright (c) 2026 TheNewswire - All rights reserved.